-+ 0.00%
-+ 0.00%
-+ 0.00%

Opko Health takes 15% stake in Nicoya Therapeutics under amended RAYALDEE deal

PUBT·04/30/2026 12:33:15
Listen to the news
Opko Health takes 15% stake in Nicoya Therapeutics under amended RAYALDEE deal
  • Opko Health secured a 15% equity stake in Nicoya Therapeutics (Macau) under an amended RAYALDEE commercialization agreement for Greater China.
  • Equity issuance of Series A-2 Preferred Shares is set to close in two tranches.
  • Opko exchanged revised tiered royalty terms and transfer pricing for minority stake.
  • Milestone structure remained unchanged, leaving Opko eligible for up to USD 115 million tied to development, regulatory, and sales triggers.
  • Companies expect regulatory approvals in China and related territories in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300830PRIMZONEFULLFEED9710459) on April 30, 2026, and is solely responsible for the information contained therein.